From a scientific vision in 2018 to an integrated technology platform and expanding global collaborations in 2026.
BEIJING, China – November 2026 – Daxiang Biotech marks its eighth anniversary, celebrating eight years of advancing organoid and organoid-on-a-chip technologies, developing innovative research solutions, and supporting the translation of human-relevant models into drug discovery and development.
Since its founding in Beijing in 2018, Daxiang Biotech has remained committed to addressing the limitations of conventional research models through innovative organoid technologies. What began as a scientific vision has evolved into an integrated technology platform encompassing microfluidic chips, proprietary instruments, organoid and disease models, culture solutions, and intelligent data analysis.
Over the past eight years, Daxiang Biotech has progressed through several important stages of development.
2018–2020 | Foundation
Following its establishment in Beijing, Daxiang introduced its early commercial organoid-on-a-chip products and began building collaborations with pharmaceutical companies, laying the foundation for its technology development and commercialization.
2021–2022 | Scientific Validation
The company advanced applications of its IBAC® chip platforms, including liver toxicity and kidney proximal tubule models, while expanding research collaborations and exploring new applications in organoid-based research.
2023–2025 | Translational Development
With the launch of OrganoidBOX, Daxiang further expanded its portfolio of disease models, proprietary instruments, and specialized culture solutions. Its technologies continued to support research and drug-development programs across multiple application areas.
2026 | Global Engagement
Daxiang strengthened its international presence through participation in four major scientific and industry conferences in the United States: the MPS World Summit, BIO International Convention, Tumor Models Summit, and SITC Annual Meeting. The company also established the Organoid and Organoid-on-a-Chip Innovation R&D Center with Molecular Devices in November 2026, marking a new milestone in collaborative technology development.
Today, Daxiang Biotech has developed an integrated technology platform designed to support complementary stages of the organoid research workflow.
Its portfolio brings together five key capabilities:
IBAC® Chip Platforms: Microfluidic platforms designed for organoid-on-a-chip applications.
Oukoryn™ Instruments: Proprietary instruments supporting organoid culture, imaging, and analysis.
Organoid and Disease Models: Research models supporting disease studies and drug evaluation.
Culture Kits and Reagents: Specialized solutions for organoid research workflows.
Intelligent Data Analysis: Data-driven tools supporting drug efficacy and toxicity assessment.
By integrating these capabilities, Daxiang aims to provide researchers with more comprehensive and adaptable solutions for organoid research, disease modeling, and drug development.
Beyond technology development, Daxiang continues to explore the practical applications of organoid technologies in drug discovery and translational research.
The company's organoid technologies have reached an important translational milestone, with five IND submissions. Its application portfolio spans oncology models, barrier models, organ-specific models, and tumor microenvironment research.
These applications support a broad range of research needs, including disease modeling, drug efficacy assessment, toxicity evaluation, and translational research.
Through continued technology development and research collaboration, Daxiang seeks to contribute to more human-relevant approaches to evaluating drug responses and advancing preclinical research.
Scientific research and technological innovation remain central to Daxiang Biotech's development.
The company's technologies have been featured in selected peer-reviewed research publications covering organoid models, organoid-on-a-chip systems, disease modeling, and translational applications.
Its innovation portfolio includes 29 invention patents, 3 PCT applications, and 9 software copyrights, reflecting its continued investment in proprietary technology development.
Daxiang also maintains an ISO 9001-certified Quality Management System, supporting its commitment to quality management and operational standards.
The company's achievements have received recognition from the industry, including:
2021: Deloitte China Rising Star
2026: Second Prize, HICOOL Global Entrepreneurship Competition
2026: Top Organoids-on-Chips Model Services in Asia, Life Sciences Review APAC
As Daxiang enters its next stage of development, international engagement and cross-industry collaboration are becoming increasingly important.
In 2026, the company participated in four major US conferences, engaging with researchers, pharmaceutical companies, biotechnology innovators, and industry partners across the global life sciences community.
Another significant milestone was the establishment of the Organoid and Organoid-on-a-Chip Innovation R&D Center with Molecular Devices in November 2026. The collaboration aims to explore opportunities in organoid research, high-content imaging, automated cell culture, and intelligent analysis, bringing complementary technologies and expertise together to support future innovation.
These initiatives reflect Daxiang's continued efforts to strengthen international connections and explore collaborative opportunities across the life sciences industry.
Eight years of innovation have laid a strong foundation for Daxiang Biotech's continued development. Looking ahead, the company remains committed to advancing organoid and organoid-on-a-chip technologies, expanding its integrated technology platform, strengthening global collaborations, and enabling more human-relevant approaches to drug discovery and development.
As Daxiang moves forward, it will continue working alongside researchers, customers, and partners to explore new possibilities in life sciences research.
Eight years of innovation. A new chapter of possibilities.